New Yorker reporter Dhruv Khullar spotlights how researchers from across MIT are using AI to advance drug development. Khullar highlights the MIT Jameel Clinic, the Broad Institute and various faculty members for their efforts in bridging the gap between AI and drug research. “With AI, we’re getting that much more efficient at finding molecules—and in some cases creating them,” says Prof. James Collins. “The cost of the search is going down. Now we really don’t have an excuse.”
Prof. Daron Acemoglu is a guest on the Financial Times podcast, “The Economics Show with Soumaya Keynes," detailing his research on the economics of AI and implications for workers. He says AI could help the current workforce communicate better and control its own data, while opening up possibilities for the geographically or economically disadvantaged, if the right policies are put in place. “I think having this conversation, and really making it a central part of the public debate that there is a technically feasible and socially beneficial different direction of technology, would have a transformative effect on the tech sector,” he explains.
Researchers from MIT and Northwestern University have developed some guidelines for how to spot deepfakes, noting “there is no fool-proof method that always works,” reports Jeremy Hsu for New Scientist.
Writing for Forbes, Andrew Binns highlights research from Prof. Daron Acemoglu suggesting total productivity gains of AI could be as little as 0.53% over 10 years, much lower than common estimates.
Senior lecturer Paul McDonagh-Smith speaks with Forbes reporter Joe Mckendrick about the history behind the AI hype cycle. “While AI technologies and techniques are at the forefront of today’s technological innovation, it remains a field defined — as it has from the 1950s — by both significant achievements and considerable hype," says McDonagh-Smith.
Researchers at MIT are working toward training AI models “as subject-matter experts that ethically tailor financial advice to an individual’s circumstances,” reports Tanza Loudenback for Business Insider. “We think we’re about two or three years away before we can demonstrate a piece of software that by SEC regulatory guidelines will satisfy fiduciary duty,” says Prof. Andrew Lo.
TechCrunch reporter Kyle Wiggers spotlights Codeium, a generative AI coding company founded by MIT alums Varun Mohan SM '17 and Douglas Chen '17. Codeium’s platform is run by generative AI models trained on public code, providing suggestions in the context of an app’s entire codebase. “Many of the AI-driven solutions provide generic code snippets that require significant manual work to integrate and secure within existing codebases,” Mohan explains. “That’s where our AI coding assistance comes in.”
MIT alumni Mike Ng and Nikhil Buduma founded Ambiance, which has developed an “AI-powered platform geared towards improving documentation processes in medicine,” reports Fortune’s Allie Garfinkle. “In a world filled with AI solutions in search of a problem, Ambience is focusing on a pain point that just about any doctor will attest to (after all, who likes filling out paperwork?),” writes Garfinkle.
Writing for The Boston Globe, President Emeritus L. Rafael Reif makes the case that “without strong research universities and the scientific and technological advances they discover and invent, the United States could not possibly keep up with China.” He emphasizes that “punishing universities financially for their failings — real and imagined — would be counterproductive. If anything, the China challenge demands that universities do more than they are already doing — and that they have the resources to do so.”
Prof. William Deringer speaks with David Westin on Bloomberg’s Wall Street Week about the power of early spreadsheet programs in the 1980s financial services world. When asked to compare today’s AI in the context of workplace automation fears, he says “one thing we know from the history of technology - and certainly the history of calculation tools that I like to study – is that the automation of some of these calculations…doesn’t necessarily lead to less work.”
Researchers at MIT have developed “a publicly available database, culled from reports, journals, and other documents to shed light on the risks AI experts are disclosing through paper, reports, and other documents,” reports Jon McKendrick for Forbes. “These benchmarked risks will help develop a greater understanding the risks versus rewards of this new force entering the business landscape,” writes McKendrick.
A new database of AI risks has been developed by MIT researchers in an effort to help guide organizations as they begin using AI technologies, reports Will Knight for Wired. “Many organizations are still pretty early in that process of adopting AI,” meaning they need guidance on the possible perils, says Research Scientist Neil Thompson, director of the FutureTech project.
TechCrunch reporter Kyle Wiggers writes that MIT researchers have developed a new tool, called SigLLM, that uses large language models to flag problems in complex systems. In the future, SigLLM could be used to “help technicians flag potential problems in equipment like heavy machinery before they occur.”
MIT researchers have developed an AI risk repository that includes over 70 AI risks, reports Kyle Wiggers for TechCrunch. “This is an attempt to rigorously curate and analyze AI risks into a publicly accessible, comprehensive, extensible and categorized risk database that anyone can copy and use, and that will be kept up to date over time,” explains Peter Slattery, a research affiliate at the MIT FutureTech project.
Prof. Regina Barzilay joins BBC host Caroline Steel and other AI experts to discuss her inspiration for applying AI technologies to help improve medicine and fight cancer. “I think that in cancer and in many other diseases, the big question is always, how do you deal with uncertainty? It's all the matter of predictions," says Barzilay. "Unfortunately, today, we rely on humans who don't have this capacity to make predictions. As a result, many times people get wrong treatments or they are diagnosed much later.”